Inhibrx Biosciences, Inc. SEC filings INBX
Inhibrx Biosciences, Inc. has 158 filings in SEC EDGAR's recent list, going back to Jan 29, 2024. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
|
Jul 16, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 15, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 11, 2026 | May 11, 2026 |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 21, 2026 | Apr 21, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 19, 2026 | Mar 19, 2026 |
| 10-K | Annual report | Mar 19, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 23, 2026 | Feb 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 16, 2025 | Dec 16, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2025 | Nov 14, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 23, 2025 | Oct 23, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2025 | Aug 13, 2025 |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| EFFECT | Filing | Jun 4, 2025 | — |
| POS AM | Filing | Jun 2, 2025 | — |
| 424B3 | Prospectus | May 28, 2025 | — |
| 8-K |
Current report
Shareholder vote results
|
May 28, 2025 | May 28, 2025 |
| 424B3 | Prospectus | May 14, 2025 | — |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| EFFECT | Filing | Apr 18, 2025 | — |
| POS AM | Filing | Apr 17, 2025 | — |
| ARS | Annual report to shareholders | Apr 17, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 16, 2025 | — |
| DEF 14A | Proxy statement | Apr 16, 2025 | Dec 31, 2024 |
| 424B3 | Prospectus | Apr 1, 2025 | — |
| 8-K |
Current report
Officer or director change
|
Apr 1, 2025 | Mar 31, 2025 |
| POS EX | Filing | Mar 17, 2025 | — |
| 424B3 | Prospectus | Mar 17, 2025 | — |
| 8-K |
Current report
Results of operations
|
Mar 17, 2025 | Mar 17, 2025 |
| 10-K | Annual report | Mar 17, 2025 | Dec 31, 2024 |
| 424B3 | Prospectus | Jan 21, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 21, 2025 | Jan 21, 2025 |
| 424B3 | Prospectus | Jan 13, 2025 | — |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure
|
Jan 13, 2025 | Jan 13, 2025 |
| 424B3 | Prospectus | Nov 14, 2024 | — |
| 8-K |
Current report
Results of operations
|
Nov 14, 2024 | Nov 14, 2024 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| 424B3 | Prospectus | Nov 4, 2024 | — |
| 8-K |
Current report
Other events
|
Nov 4, 2024 | Nov 4, 2024 |
| 424B3 | Prospectus | Aug 14, 2024 | — |
| 424B3 | Prospectus | Aug 13, 2024 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2024 | Aug 13, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| EFFECT | Filing | Jun 18, 2024 | — |
| 424B3 | Prospectus | Jun 18, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 17, 2024 | Jun 17, 2024 |
| CORRESP | Letter to the SEC | Jun 14, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2024 | — |
| S-1 | Registration statement | Jun 11, 2024 | — |
| S-8 | Employee stock plan registration | May 30, 2024 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Other events
|
May 30, 2024 | May 29, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
May 24, 2024 | May 24, 2024 |
| SEC STAFF ACTION | Filing | May 24, 2024 | — |
| CERT | Filing | May 24, 2024 | — |
| CORRESP | Letter to the SEC | May 22, 2024 | — |
| 10-12B/A | Filing | May 15, 2024 | — |
| 10-12B/A | Filing | May 8, 2024 | — |
| CORRESP | Letter to the SEC | Apr 25, 2024 | — |
| 10-12B | Filing | Apr 25, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2024 | — |
| DRSLTR | Filing | Mar 4, 2024 | — |
| DRS/A | Filing | Mar 4, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 29, 2024 | — |
| DRS | Filing | Jan 29, 2024 | — |
Showing 75 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INBX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2007919
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.